Cortendo names new chair
This article was originally published in Scrip
Executive Summary
Cortendo, a global biopharmaceutical company focused on orphan endocrine disorders, has appointed John H Johnson chair of its board of directors and named Richard Kollender a director. These appointments, proposed by the nomination committee, were approved by shareholders during the Extraordinary General Meeting on 17 March. Mr Johnson has more than 30 years of biopharmaceutical industry experience at organizations including Johnson & Johnson, Lilly, ImClone and Pfizer. He is currently a member of the board of directors of Cempra Pharmaceuticals, Histogenics, Portola Pharmaceuticals, and Sucampo Pharmaceuticals. He previously served as chair of Dendreon and Tranzyme Pharma, and also served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), and BioNJ.